http://www.trichoscience.com/
ξερω οτι υπαρχει (εγω το ξεκινησα) αλλα ανοιγω ενα νεο θεμα με αφορμη και ενα mail που ελαβα με τα latest news
Dr. Erich Mohr Appointed Chairman of TrichoScience
>
> February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
> (TrichoScience) has announced the appointment of Dr. Erich Mohr
> (PhD, R.Psych) as the Company's new Chairman of the Board of
> Directors, effective immediately. Dr. Mohr also serves as
> Chairman and CEO of MedGenesis Therapeutix Inc., a company he
> founded in 2006.
>
> Dr. Mohr, who was a Professor of Medicine and Psychology at the
> University of Ottawa until 1997, has over 25 years of experience
> in experimental therapeutics of CNS disorders. He is credited
> with over 150 publications, books, book chapters and abstracts
> and has edited the, Handbook of Clinical Trials: The
> neurobehavioral approach. Dr. Mohr has chaired and/or served
> on several regulatory advisory panels for the approval of new
> products for the treatment of neurodegenerative disease. He is
> the former Chairman and Chief Executive Officer of CroMedica
> Global Inc., which was merged with PRA International in 2002,
> and co-founder of several biotechnology companies. Prior to his
> founding of MedGenesis, he served as Chief Scientific Officer
> for PRA International. PRA is one of the top five contract
> research organizations in the world. Over the course of his
> career, Dr. Mohr has overseen and/or participated in dozens of
> clinical development programs resulting in a number of approved
> drugs.
>
> In announcing the appointment, former TrichoScience Chairman,
> Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
> Chairmanship of TrichoScience marks an important milestone in
> the development of our Company. He brings a depth of invaluable
> experience that will help shape and guide the Company as it
> heads into one of its most important periods of growth and
> maturity. His knowledge of and direct participation in both
> clinical trials and the regulatory approvals' process brings a
> level of hands-on experience and a base of knowledge that will
> be of significant benefit to the Company at this time."
>
> Concurrent with Dr. Mohr's appointment, Dr. McLean has been
> named Chairman of TrichoScience's new Corporate Advisory Board.
>
>
>
>
> About TrichoScience
> TrichoScience Innovations Inc. (TrichoScience) is a
> privately-held life sciences company based in Vancouver,
> Canada. The company is developing a new hair cell replication
> technique that has the potential to become the world's first
> non-surgical, permanent cure for pattern baldness and general
> hair loss in both men and women. The procedure, a non-surgical,
> cellular implantation method that replicates a patient's hair
> cells from their own healthy hair follicles, is being developed
> by a team of recognized research scientists and medical experts
> in the fields of hair growth, hair biology and dermatology.
> Patents covering the procedure have been issued in a number of
> international jurisdictions and are patent-pending in other
> major countries worldwide.
>
> The TrichoScience procedure is not yet commercially available
> and is subject to human clinical trials followed by regulatory
> submission, review and approvals in Canada, Europe and the
> United States.
>
> Please visit our website at http://www.trichoscience.com
>
>
> Disclaimer
> Except for historical information, this news or information
> release may contain statements that reflect the Company's
> current expectations regarding future events. Such statements
> are subject to a number of risks and uncertainties, including
> changing market conditions, successful and timely completion of
> clinical studies, establishment of corporate alliances, the
> impact of competitive products and pricing, issues related to
> the regulatory approval process and other risks that may be
> detailed in the Company's ongoing reporting.
ξερω οτι υπαρχει (εγω το ξεκινησα) αλλα ανοιγω ενα νεο θεμα με αφορμη και ενα mail που ελαβα με τα latest news
Dr. Erich Mohr Appointed Chairman of TrichoScience
>
> February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
> (TrichoScience) has announced the appointment of Dr. Erich Mohr
> (PhD, R.Psych) as the Company's new Chairman of the Board of
> Directors, effective immediately. Dr. Mohr also serves as
> Chairman and CEO of MedGenesis Therapeutix Inc., a company he
> founded in 2006.
>
> Dr. Mohr, who was a Professor of Medicine and Psychology at the
> University of Ottawa until 1997, has over 25 years of experience
> in experimental therapeutics of CNS disorders. He is credited
> with over 150 publications, books, book chapters and abstracts
> and has edited the, Handbook of Clinical Trials: The
> neurobehavioral approach. Dr. Mohr has chaired and/or served
> on several regulatory advisory panels for the approval of new
> products for the treatment of neurodegenerative disease. He is
> the former Chairman and Chief Executive Officer of CroMedica
> Global Inc., which was merged with PRA International in 2002,
> and co-founder of several biotechnology companies. Prior to his
> founding of MedGenesis, he served as Chief Scientific Officer
> for PRA International. PRA is one of the top five contract
> research organizations in the world. Over the course of his
> career, Dr. Mohr has overseen and/or participated in dozens of
> clinical development programs resulting in a number of approved
> drugs.
>
> In announcing the appointment, former TrichoScience Chairman,
> Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
> Chairmanship of TrichoScience marks an important milestone in
> the development of our Company. He brings a depth of invaluable
> experience that will help shape and guide the Company as it
> heads into one of its most important periods of growth and
> maturity. His knowledge of and direct participation in both
> clinical trials and the regulatory approvals' process brings a
> level of hands-on experience and a base of knowledge that will
> be of significant benefit to the Company at this time."
>
> Concurrent with Dr. Mohr's appointment, Dr. McLean has been
> named Chairman of TrichoScience's new Corporate Advisory Board.
>
>
>
>
> About TrichoScience
> TrichoScience Innovations Inc. (TrichoScience) is a
> privately-held life sciences company based in Vancouver,
> Canada. The company is developing a new hair cell replication
> technique that has the potential to become the world's first
> non-surgical, permanent cure for pattern baldness and general
> hair loss in both men and women. The procedure, a non-surgical,
> cellular implantation method that replicates a patient's hair
> cells from their own healthy hair follicles, is being developed
> by a team of recognized research scientists and medical experts
> in the fields of hair growth, hair biology and dermatology.
> Patents covering the procedure have been issued in a number of
> international jurisdictions and are patent-pending in other
> major countries worldwide.
>
> The TrichoScience procedure is not yet commercially available
> and is subject to human clinical trials followed by regulatory
> submission, review and approvals in Canada, Europe and the
> United States.
>
> Please visit our website at http://www.trichoscience.com
>
>
> Disclaimer
> Except for historical information, this news or information
> release may contain statements that reflect the Company's
> current expectations regarding future events. Such statements
> are subject to a number of risks and uncertainties, including
> changing market conditions, successful and timely completion of
> clinical studies, establishment of corporate alliances, the
> impact of competitive products and pricing, issues related to
> the regulatory approval process and other risks that may be
> detailed in the Company's ongoing reporting.